Rheumatoid arthritis (RA) and psoriatic arthritis (PsA) are both chronic inflammatory conditions that cause joint pain, swelling, and stiffness, but they arise from different immune system pathways, affect different joints, and respond to different treatments. Telling them apart matters because the wrong diagnosis can mean the wrong therapy. Here’s how they differ in ways that actually affect your experience and care.
What Drives the Inflammation
Both conditions involve an overactive immune system attacking the body’s own tissues, but the specific immune cells and chemical signals doing the damage are not the same. RA involves both T cells and B cells flooding the joint lining, and it produces measurable autoantibodies (proteins that mistakenly target your own tissues) that circulate in the blood. PsA, by contrast, is driven primarily by T cells, with fewer B cells involved. PsA also shows early growth of new blood vessels in the inflamed tissue, while RA develops that feature later.
This distinction explains a practical difference in treatment. Therapies that deplete B cells or block a signaling molecule called IL-6 work well for RA but not for PsA. Meanwhile, PsA responds to drugs that target a different inflammatory pathway involving IL-17 and IL-23, signaling molecules that are overproduced by a specific subset of T cells. Both conditions respond to TNF-blocking drugs, which is one reason they can initially look similar from a treatment standpoint.
Which Joints Are Affected
The pattern of joint involvement is one of the clearest ways to tell these two conditions apart. RA tends to be symmetrical: if the knuckles on your left hand are swollen, the same knuckles on your right hand typically are too. It commonly targets the wrists, the large knuckles at the base of the fingers, the middle finger joints, and corresponding joints in the feet, along with shoulders, elbows, hips, knees, and ankles.
PsA often starts out asymmetrical, affecting one side more than the other, though it can become more symmetrical as more joints get involved over time. A hallmark difference is that PsA frequently affects the joints closest to your fingertips and toenails (the distal joints), which RA almost never does. PsA also commonly involves the lower spine, sacroiliac joints at the base of the spine, and large joints in the legs. It can affect the wrists and base-of-finger knuckles too, which adds to the diagnostic confusion.
Sausage Fingers and Tendon Pain
Two features are strongly associated with PsA and rare in RA: dactylitis and enthesitis.
Dactylitis is the swelling of an entire finger or toe, giving it a puffy, sausage-like appearance. It occurs in roughly 16% to 49% of people with PsA and can be the first sign of the disease. While dactylitis can show up in a few other conditions like gout, it’s uncommon enough in RA that its presence is a strong clue pointing toward PsA.
Enthesitis is inflammation where tendons and ligaments attach to bone. Common spots include the Achilles tendon, the bottom of the heel, and the areas around the elbows and knees. This type of pain feels different from joint pain because it’s localized to the connection point rather than inside the joint itself. Enthesitis is considered a defining feature of PsA and is built into the formal classification criteria for the disease.
Skin and Nail Changes
The most obvious distinguishing feature is skin involvement. Most people with PsA develop the scaly, red or silvery patches of psoriasis before any joint symptoms appear, sometimes years earlier. About 85% of PsA patients have skin psoriasis that predates their arthritis. If you already have psoriasis and start developing joint pain, PsA is a strong possibility.
Nail changes are another telling sign. PsA often causes tiny dents (pitting) in the fingernails or toenails, along with brittleness, crumbling, or nails lifting away from the nail bed. RA does not cause these nail changes. Since the joints closest to the nails are the ones PsA targets, nail symptoms and nearby joint inflammation often go hand in hand.
Blood Tests and Biomarkers
Blood work is one of the most useful tools for separating these two diagnoses. RA produces autoantibodies that PsA typically does not.
Rheumatoid factor (RF) is positive in a majority of RA patients. Its specificity for RA is around 85%, meaning 15% of positive results come from people with other conditions. A more precise test is anti-CCP (a test for antibodies against a specific protein fragment), which has a specificity of 95% to 96% for RA. Anti-CCP shows up in 1.5% or fewer of healthy people and in 10% or fewer of those with other rheumatic diseases.
PsA is typically seronegative, meaning these autoantibodies are absent. The formal classification criteria for PsA allow for low levels of rheumatoid factor without ruling out the diagnosis, but high levels of RF or anti-CCP strongly favor RA. If your blood tests are negative for both markers and you have joint inflammation, PsA (or another seronegative arthritis) is more likely than RA.
Who Gets Each Condition
RA affects roughly 0.5% to 1% of the global population, making it significantly more common than PsA, which has a worldwide prevalence of about 112 per 100,000 adults (just over 0.1%). RA is two to three times more common in women than men. PsA affects men and women equally, with most cases becoming symptomatic between ages 30 and 60.
Genetics play a role in both, but through different pathways. RA is strongly associated with a genetic marker called HLA-DR4, and people with RA are more likely to carry multiple copies of related gene variants. PsA is linked instead to HLA-B27 (a marker shared with other spine-related inflammatory conditions) and HLA-B7. Having these markers doesn’t guarantee you’ll develop either disease, but they help explain why the two conditions run in different families and behave differently.
How Diagnosis Works
The classification criteria for each condition reflect their biological differences. For RA, the 2010 ACR/EULAR criteria use a scoring system that weighs the number and type of joints involved, blood test results (RF and anti-CCP levels), markers of inflammation, and how long symptoms have lasted. These newer criteria were designed to catch RA earlier than the older 1987 rules, which required damage that had often already occurred.
PsA is classified using the CASPAR criteria, developed in 2004, which are 92% sensitive and 99% specific. Notably, CASPAR can diagnose PsA even without active arthritis if features like dactylitis, enthesitis, nail changes, or a personal or family history of psoriasis are present. This flexibility reflects the reality that PsA doesn’t always look like a straightforward arthritis at first.
Treatment Differences
Both conditions are treated with anti-inflammatory medications and disease-modifying drugs, but the biologic therapies that work best diverge significantly. TNF-blocking drugs remain effective for both RA and PsA and are often a first-line biologic option in either case.
Beyond TNF blockers, the paths split. RA responds well to drugs that target B cells or block IL-6 signaling. These same drugs do not work for PsA. Instead, PsA benefits from biologics that block IL-17 (such as secukinumab, ixekizumab, and bimekizumab), IL-23 (guselkumab, risankizumab, tildrakizumab), or both IL-12 and IL-23 (ustekinumab). These drugs address the specific inflammatory cascade driving PsA and can improve both joint and skin symptoms simultaneously.
This is one of the most practical reasons an accurate diagnosis matters. If you have PsA but are being treated as though you have RA, you may be given medications that won’t address the underlying immune pathway. The reverse is also true. Getting the right label leads to the right drug class, which leads to better long-term control of inflammation and less joint damage over time.